Project Grant R01DE035644
- The National Institute of Dental and Craniofacial Research awarded Regents of the University of Michigan $312,000 on March 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate retinoic acid signaling in ameloblast differentiation during dental enamel formation. The research integrates single-cell RNA-sequencing data from 14 studies across mouse, rat, and human tooth development to determine ameloblast differentiation trajectories and elucidate the role...
- The National Institute of Dental and Craniofacial Research awarded the University of New Hampshire $299,950 on August 19, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop a functional smoothed deep learning approach combining deep neural networks and functional data analysis techniques for analyzing high-dimensional genetic data associated with orofacial clefts and predicting disease risk. The research will build and validate a functional smoothed deep...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $920,152 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a study examining the access, timing, and impact of dental care on health outcomes in children with sickle cell disease. The research uses national Medicaid data to determine whether preventive dental care improves outcomes for children with sickle cell disease and whether some children would...
- The National Institute of Dental and Craniofacial Research awarded the Stowers Institute For Medical Research $371,250 on March 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the pathogenesis, phenotypic variation, and prevention of craniofacial anomalies. The project examines how genetic and environmental factors interact to produce craniofacial birth defects—conditions such as cleft lip and palate, micrognathia, and craniosynostosis that account...
- The National Institute of Dental and Craniofacial Research awarded $593,876 to the Regents of the University of Michigan on August 7, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the molecular mechanisms regulating peritubular dentin mineralization and develop bioengineered strategies for targeted dentin reconstruction. The research uses six mouse models with varied amounts of dentin sialoprotein (DSP), dentin phosphoprotein (DPP), and chondroitin...
- The National Institute of Dental and Craniofacial Research awarded The University of Iowa $311,000 on July 9, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to conduct functional analysis of genetic-epigenetic interplay in orofacial clefts. The award funds research examining how differential DNA methylation and genetic variation contribute to nonsyndromic orofacial cleft (OFC) etiology. Orofacial clefts affect approximately 1 in 700 individuals worldwide and cause...
- The National Institute of Dental and Craniofacial Research awarded the Regents of the University of Michigan $583,620 on August 21, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to engineer transfer RNA-derived small RNAs (tsRNAs) as species-specific antimicrobial agents targeting oral pathobionts. The funded work develops chemically modified tsRNAs to suppress dental pathogens including Fusobacterium nucleatum, Porphyromonas gingivalis, and Treponema denticola while...
- The National Institute of Dental and Craniofacial Research awarded $495,467 to Seattle Children's Hospital on August 21, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop a visual communication tool addressing craniofacial microsomia patient education and clinician communication. Craniofacial microsomia is the third most common congenital craniofacial condition, affecting approximately 1 in 3,000 to 5,600 births and presenting with variable underdevelopment of...
- The National Institute of Dental and Craniofacial Research awarded Cincinnati Children's Hospital Medical Center a project grant of $605,123 on June 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the regulation of palate development and innervation in the context of cleft palate pathology. The research addresses velopharyngeal insufficiency, a functional deficit affecting 20 to 40 percent of children who undergo surgical repair for cleft palate....
- The National Institute of Dental and Craniofacial Research awarded the Regents of the University of Michigan $429,000 on June 5, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the effects of recurrent periodontitis on hematopoietic stem cell function. The research establishes a chronic periodontitis model to examine long-term effects on hematopoietic stem cells and defines the functional consequences of chronic periodontitis on these cells, accounting...
The National Institute of Dental and Craniofacial Research awarded the Regents of the University of Michigan $710,519 on August 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to establish a comprehensive, web-based developmental monitoring system for infants and toddlers with orofacial clefts. The project will track developmental status and trajectories across multiple domains—social/communication/cognition skills, motor abilities, early relational health, sleep, and feeding/elimination—in a large, multi-site cohort with nonsyndromic cleft lip and/or cleft palate using the empirically validated PEDIATRAC methodology. PEDIATRAC is a low-cost, caregiver-based online assessment tool that gathers longitudinal data across the first 18 months of life and measures growth trajectories to detect deviations more sensitively than cross-sectional assessments. The project will identify infants and toddlers at risk for neurodevelopmental deviations and establish a monitoring system to enhance early identification and guide early intervention referrals, addressing the current gap in clinical guidelines for comprehensive serial developmental assessments and tracking of surgical intervention effects in this population. Performance takes place in Ann Arbor, Michigan, with a period of performance from August 1, 2026, through July 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $710.5k | 7/28/26 |